Warren Austin
Internal Medicine · Va Beach, VANPI 1700851953
Payments from drug & device makers
Across 347 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$850
- AstraZeneca$717
- Novo Nordisk$546
- Lilly USA, LLC$377
- Pfizer$356
- Amarin Pharma, Inc.$321
- plus $2K from 36 others
What the payments were for
- Food & beverage$5,636100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$223
- SYMBICORT$118
- BREZTRI AEROSPHERE$118
How this compares
$5,642 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 26 | $33,793 |
| OzempicSemaglutide | 18 | $22,682 |
| EliquisApixaban | 13 | $18,802 |
| MounjaroTirzepatide | 15 | $13,207 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,064 |
| Levothyroxine Sodium | 71 | $1,021 |
| Losartan Potassium | 74 | $954 |
| Rosuvastatin Calcium | 69 | $842 |
| Atorvastatin Calcium | 102 | $836 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $792 |
| Celecoxib | 24 | $586 |
| Amlodipine Besylate | 73 | $552 |
| Metoprolol Succinate | 33 | $513 |
| Zolpidem Tartrate | 88 | $510 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 26 | $508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $717 | $33,79326 claims |
| Novo NordiskOzempic | $546 | $22,68218 claims |
| PfizerEliquis | $356 | $18,80213 claims |
| Lilly USA, LLCMounjaro | $377 | $13,20715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Va Beach
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.